Abstract

• Discovering how next generation precision reprogramming technology, opti-oxTM, is overcoming the inefficiencies and inconsistencies of current cell generation methods • Understanding how precision reprogramming is powering a new class of rapidly maturing, consistent and scalable human iPSC-derived cells (glutamatergic neurons, GABAergic neurons and microglia) and associated disease models for neurodegenerative disorders such as Gaucher’s, Huntington’s and Parkinson’s disease • Exploring insights into CNS drug discovery case studies | Compatibility of ioGlutamatergic Neurons for high throughput screening and the application of opti-ox powered GBA and Parkinson’s disease models in functional phenotypic screens